Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmhn linvoseltamab‑gcpt (Lynozyfic) Coverage | Open…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.743

    Linvoseltamab-gcpt (Lynozyfic) coverage

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.743 alerts

    Get alerted when Policy CP.PHAR.743 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed or refractory multiple myeloma in adults, and approval durations across lines of business.

    Policy Summary
    Payermhn
    PolicyLinvoseltamab-gcpt (Lynozyfic) coverage
    Policy CodePolicy CP.PHAR.743
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review Date
    Key ActionPrior authorization is required; provider must submit documentation (office chart notes, lab results, or other clinical information) demonstrating diagnosis, prior therapies, dosing, and that member meets coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥4Required prior lines of therapy
    ≥18Minimum age
    6 moInitial approval duration
    12 moContinued therapy (Medicaid/HIM)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Boxed warnings
    J9601Primary HCPCS

    Coverage Criteria for Linvoseltamab-gcpt (Lynozyfic)

    inv-01: Initial Therapy — Multiple Myeloma — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Initial MM criteria: 1. Diagnosis of multiple myeloma; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Disease is relapsed or refractory; 5. Either (a) measurable disease assessed within the last 28 days as evidenced by one of: serum M protein ≥ 0.5 g/dL OR urine M protein ≥ 200 mg/24 h OR involved serum free light chain (FLC) ≥ 10 mg/dL with abnormal kappa/lambda FLC ratio; OR (b) progressive disease per IMWG response criteria assessed within 60 days after the last dose of the last anti-myeloma regimen; 6. Member has received or has documented intolerance to ≥ 4 prior lines of therapy that include: (a) one proteasome inhibitor; (b) one immunomodulatory agent; and (c) one anti-CD38 monoclonal antibody; 7. No known multiple myeloma brain lesions or meningeal involvement; 8. Requested dose meets one of the following: (a) does not exceed the specified step-up and maintenance schedule (Day 1: 5 mg; Day 8: 25 mg; Day 15: 200 mg; then weekly 200 mg for Week 4–13 [10 weekly doses]; then 200 mg every 2 weeks from Week 14 onward); OR (b) dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN

    inv-02: Continued Therapy — Multiple Myeloma — Continued coverage when ALL of the following are met:

    Continued coverage when ALL of the following are met:

    Continued therapy criteria: 1. Member is currently receiving linvoseltamab-gcpt via the benefit, or documentation supports the member has received Lynozyfic for a covered indication for at least 30 days; 2. Member is responding positively to therapy; 3. If the request is for a dose increase, one of the following applies: (a) new dose does not exceed 200 mg every 2 weeks; OR (b) for members who have achieved and maintained very good partial response (VGPR) or better at or after week 24 and who received at least 17 doses of 200 mg, dosing may be 200 mg every 4 weeks; OR (c) new dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN

    inv-03: Initial and Maintenance Dosing — Covered when dosing and scheduling align with the FDA-approved regimen for MM:

    Covered when dosing and scheduling align with the FDA-approved regimen for MM:

    Step-up and maintenance dosing: Member receives linvoseltamab-gcpt per the step-up schedule: Day 1: 5 mg IV; Day 8: 25 mg IV; Day 15: 200 mg IV (first treatment dose). Thereafter, weekly dosing from Week 4 to Week 13: 200 mg IV once weekly (10 weekly doses), followed by maintenance 200 mg IV every 2 weeks from Week 14 onward. Patients who have achieved and maintained VGPR or better at or after week 24 and received at least 17 doses of 200 mg may receive 200 mg IV every 4 weeks.VGPR at/after week 24 & >=17 doses

    Includes step-up doses and maintenance schedule per product labeling

    Non–FDA approved indications not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with applicable off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (Health Insurance Marketplace/ICHRA), or CP.PMN.53 (Medicaid), or unless evidence of coverage documents permit the use.

    The pivotal LINKER‑MM1 trial excluded patients with central nervous system involvement; specifically, patients with multiple myeloma with brain lesions or meningeal involvement were not enrolled and are an exclusion in the trial population.

    Inclusion of a billing code in this policy is informational only; coding inclusion does not guarantee coverage. Coverage determinations remain subject to plan‑specific medical necessity rules and benefit language, and providers should follow the payer’s medical necessity and claims submission requirements.

    Initial Therapy — Authorization and Dosing Requirements

    inv-24: Initial therapy — initial approval criteria and dosing limits.

    Initial approval criteria and dosing limits

    Initial therapy: Member meets diagnosis and provider requirements (diagnosis of MM; prescribed by or in consultation with an oncologist/hematologist), is age ≥18, has relapsed or refractory disease, and meets measurable disease or IMWG‑defined progression criteria. Member has received or has intolerance to ≥4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. Member has no known MM brain lesions or meningeal involvement. Requested dosing does not exceed the specified step‑up and maintenance dosing schedule (Day 1: 5 mg; Day 8: 25 mg; Day 15: 200 mg; weekly 200 mg Week 4–13 for 10 doses; then 200 mg every 2 weeks thereafter), or the dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN

    inv-25: Initial Therapy — initial dosing regimen for treatment of MM per product labeling.

    Initial dosing regimen for treatment of MM per product labeling:

    Initial step-up and weekly dosing:

    Criteria for Continued and Maintenance Therapy

    inv-26: Continued therapy — criteria for continued therapy and durations.

    Criteria for continued therapy and durations

    Continued therapy: 1. Member has been receiving linvoseltamab-gcpt for at least 30 days or documentation shows current receipt via the benefit; 2. Member is demonstrating a positive response to therapy; 3. Dose increases must comply with policy limits: new dose must not exceed 200 mg every 2 weeks, except that members who have achieved and maintained VGPR or better at or after week 24 and received at least 17 doses of 200 mg may receive 200 mg every 4 weeks; alternatively, any increase must be supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

    Approval durations: Medicaid/HIM/ICHRA 12 months; Commercial 6 months or to member renewal date

    inv-27: Maintenance Therapy — maintenance/continuation dosing rules per labeling.

    Maintenance/continuation dosing rules per labeling:

    Continuation dosing options: After initial weekly dosing, continue 200 mg IV every 2 weeks. Patients who have achieved and maintained VGPR or better at or after week 24 and have received at least 17 doses of 200 mg may transition to 200 mg IV every 4 weeks.

    Coding, Quantity, and Measurable Criteria

    Covered HCPCS CodesHCPCSCovered
    J9601Injection, linvoseltamab-gcpt, 1 mg
    Measurable disease thresholds — serum/urine M protein and involved FLC thresholds
    Serum M protein thresholdSerum M protein ≥ 0.5 g/dL (measured within last 28 days)
    Urine M protein thresholdUrine M protein ≥ 200 mg/24 h (measured within last 28 days)
    Involved FLC thresholdInvolved serum free light chain (FLC) ≥ 10 mg/dL (100 mg/L) with abnormal kappa:lambda FLC ratio (measured within last 28 days)
    VGPR durability — achieved and maintained at or after week 24 with at least 17 doses of 200 mg
    VGPR timing requirementAchieved and maintained VGPR or better at or after week 24
    Dose count requirementMember must have received at least 17 doses of 200 mg

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization — document diagnosis, prior therapies, and dosing

    Prior authorization is required. The provider must demonstrate medical necessity by submitting documentation showing diagnosis of multiple myeloma, prior therapies received (including ≥4 prior lines with at least one proteasome inhibitor, one immunomodulatory agent, and one anti‑CD38 monoclonal antibody), and that the requested dosing follows the policy limits or is supported by practice guidelines or peer‑reviewed literature.

    • Document prior lines of therapy and intolerances (see Appendix B examples).
    • Confirm dose meets step‑up and maintenance schedule (Day 1: 5 mg; Day 8: 25 mg; Day 15: 200 mg; weekly Weeks 4–13; 200 mg every 2 weeks Week 14 onward) or provide supporting literature for off‑label dosing.
    Billing Rule

    Prior authorization and HCPCS billing (J9601)

    Therapeutic Alternatives and Step Therapy

    Therapeutic alternativeTypical regimen / notes
    bortezomib / lenalidomide (Revlimid) / dexamethasone
    Dosing regimen: varies by regimen and line of therapy; listed in Appendix B as a preferred alternative and may require prior authorization
    bortezomib / cyclophosphamide / dexamethasone
    Dosing regimen: varies; included in Appendix B as an alternative
    bortezomib / doxorubicin (or liposomal doxorubicin) / dexamethasone
    Dosing regimen: varies; listed in Appendix B
    carfilzomib (Kyprolis) / lenalidomide (Revlimid) / dexamethasone
    Dosing regimen: varies; included in Appendix B
    ixazomib (Ninlaro) / lenalidomide (Revlimid) / dexamethasone
    Dosing regimen: varies; listed as a potential alternative in Appendix B
    pomalidomide-containing regimens (e.g., pomalidomide / cyclophosphamide / dexamethasone; pomalidomide / dexamethasone; pomalidomide / bortezomib / dexamethasone)
    Dosing regimen: varies; multiple pomalidomide-based combinations are listed in Appendix B as therapeutic alternatives
    daratumumab (Darzalex or Darzalex Faspro)–containing regimens (with bortezomib/dexamethasone or with lenalidomide/dexamethasone or with pomalidomide/dexamethasone)
    Dosing regimen: varies; Darzalex combinations are included in Appendix B
    isatuximab (Sarclisa)–containing regimens (e.g., isatuximab / pomalidomide / dexamethasone; isatuximab / carfilzomib / dexamethasone)
    Dosing regimen: varies; isatuximab combinations are listed in Appendix B as alternatives
    elotuzumab (Empliciti)–containing regimens
    Dosing regimen: varies; included in Appendix B as alternative options
    Various multi-agent or intensive regimens (e.g., VTD-PACE, bendamustine-containing combinations, cyclophosphamide / lenalidomide / dexamethasone)
    Dosing regimen: varies; Appendix B lists multiple preferred alternative regimens and notes that dosing and maximum doses vary
    Therapeutic alternativeTypical regimen / notes
    pomalidomide / cyclophosphamide / dexamethasone
    Dosing regimen: varies; listed in Appendix B as a pomalidomide-containing therapeutic alternative
    pomalidomide / dexamethasone
    Dosing regimen: varies; included in Appendix B
    pomalidomide / bortezomib / dexamethasone
    Dosing regimen: varies; listed in Appendix B
    pomalidomide / carfilzomib (Kyprolis) / dexamethasone
    Dosing regimen: varies; included among pomalidomide-containing alternatives in Appendix B
    isatuximab (Sarclisa) / pomalidomide / dexamethasone
    Dosing regimen: varies; isatuximab plus pomalidomide combinations are specifically listed in Appendix B as alternatives
    isatuximab (Sarclisa) / carfilzomib / dexamethasone
    Dosing regimen: varies; listed in Appendix B as an isatuximab-containing alternative

    Site of Care and Infusion Requirements

    Note

    Approval durations set by line of business; site of care not restricted here

    The policy specifies approval durations by line of business (for example, Medicaid/HIM/ICHRA and commercial) but does not restrict the site of care in this section.

    • Approval durations differ by line of business (see policy approval duration tables).
    Documentation Required

    Infusion administration and monitoring for CRS/neurologic toxicity

    Administer linvoseltamab‑gcpt via intravenous infusion following the step‑up dosing schedule and provide appropriate monitoring for cytokine release syndrome (CRS) and neurologic toxicity, ensuring the infusion setting can manage these adverse events.

    • Step‑up dosing: Day 1: 5 mg IV; Day 8: 25 mg IV; Day 15: 200 mg IV, then weekly and biweekly maintenance per labeling.
    • Monitor for CRS and immune effector cell‑associated neurotoxicity syndrome per boxed warnings.

    Definitions and Abbreviations

    BCMA definition (B-cell maturation antigen)
    TermBCMA: B-cell maturation antigen
    ContextTarget antigen for BCMA-directed therapies used in multiple myeloma
    Abbreviation sourceDefined in Appendix A: Abbreviation/Acronym Key
    IMWG definition (International Myeloma Working Group)
    TermIMWG: International Myeloma Working Group
    RoleProvides response and progression criteria used to define disease progression in multiple myeloma
    Reference location

    Background — Product and Regulatory Context

    Linvoseltamab‑gcpt (Lynozyfic) is a BCMA‑directed bispecific CD3 T‑cell engager approved under accelerated approval for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy that include a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. Continued approval may be contingent on confirmatory trials. The product is administered by intravenous step‑up dosing and carries boxed warnings for cytokine release syndrome and neurologic toxicity; providers should reference the Lynozyfic Prescriber Information and the HCPCS billing guidance (e.g., J9601) when ordering and billing.

    Policy Summary
    Payermhn
    PolicyLinvoseltamab-gcpt (Lynozyfic) coverage
    Policy CodePolicy CP.PHAR.743
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review Date
    Key ActionPrior authorization is required; provider must submit documentation (office chart notes, lab results, or other clinical information) demonstrating diagnosis, prior therapies, dosing, and that member meets coverage criteria.
    SourceLink
    On This Page
    Coverage Criteria for Linvoseltamab-gcpt (Lynozyfic)Initial Therapy — Authorization and Dosing RequirementsCriteria for Continued and Maintenance TherapyCoding, Quantity, and Measurable CriteriaProvider Actions, Prior Authorization & DocumentationTherapeutic Alternatives and Step TherapySite of Care and Infusion RequirementsDefinitions and AbbreviationsBackground — Product and Regulatory Context
    Step‑up dosing: Day 1: 5 mg IV (step‑up dose 1); Day 8: 25 mg IV (step‑up dose 2); Day 15: 200 mg IV (first treatment dose). Weekly dosing: Week 4 to Week 13: 200 mg IV once weekly (one week after Day 15 and for 10 treatment doses).

    Follow step‑up schedule to mitigate CRS and neurologic toxicity

    VGPR at/after week 24 & >=17 doses

    Maintenance dosing adjustment described in product information

    Maintenance interval allowancePatients meeting the above may receive 200 mg IV every 4 weeks (instead of every 2 weeks)
    linvoseltamab-gcpt (Lynozyfic) — quantity limits and billing per mg schedule
    Primary billing unitBill using HCPCS J9601 (Injection, linvoseltamab-gcpt, 1 mg) — providers should confirm coding guidance
    Dose formulation and vial sizesAvailable as single-dose vials: 5 mg/2.5 mL and 200 mg/10 mL
    Quantity presentationDosing schedule based on 200 mg treatment doses; quantity limits set per mg dosing schedule (calculate units by mg billed via J9601)

    Bill linvoseltamab‑gcpt using HCPCS code J9601 (Injection, linvoseltamab‑gcpt, 1 mg) and follow the Health Plan’s prior authorization process for specialty oncology drugs.

    • Confirm coding guidance prior to claim submission; codes in policy are informational and do not guarantee coverage.
    • Follow plan administrative prior authorization procedures for specialty drugs.
    Step Therapy

    Therapeutic alternatives — see Appendix B (may require PA)

    Therapeutic alternatives are listed in Appendix B and may be considered preferred prior therapies; providers should review Appendix B and obtain prior authorization for alternative regimens when required by plan policy.

    • Appendix B lists multiple alternative regimens that may not be formulary for all lines of business and may require prior authorization.
    • Provider must document treatment history and rationale if selecting an alternative prior therapy.
    Step Therapy

    Therapeutic alternatives — pomalidomide regimens and isatuximab combos

    Appendix B specifically includes pomalidomide‑containing regimens and isatuximab (Sarclisa) combinations as listed therapeutic alternatives to linvoseltamab‑gcpt.

    • Examples include pomalidomide/dexamethasone, pomalidomide/bortezomib/dexamethasone, and Sarclisa® (isatuximab) plus pomalidomide/dexamethasone combinations as shown in Appendix B.
    Documentation Required

    Required documentation — submit office notes and lab results

    Providers must submit supporting clinical documentation (office chart notes, laboratory results, or other clinical information) to demonstrate the member meets all approval criteria when requesting authorization.

    • Include recent measurable disease data or IMWG progression documentation, prior therapy details, and any supportive evidence for off‑label dosing if applicable.
    Documentation Required

    Required documentation and coding reference — see Prescriber Info/FDA label and J9601

    Refer to the Lynozyfic Prescriber Information and FDA label for dosing and safety details and use HCPCS J9601 for billing of linvoseltamab‑gcpt; confirm coding guidance prior to claim submission.

    • Prescriber Information and the FDA label are listed as references for dosing and safety.
    • HCPCS J9601 is the policy’s billing reference for linvoseltamab‑gcpt (1 mg).
    Denial Risk

    Documentation requirement — missing documentation may lead to denial

    Failure to submit the required clinical documentation (office chart notes, lab results, or other clinical information) supporting that the member meets all approval criteria may result in denial of the prior authorization request.

    • Ensure all requested supporting records are included with the PA submission to avoid processing delays or denial.
    Denial Risk

    Coding-related denial risk — codes are informational and not a coverage guarantee

    Inclusion or exclusion of codes in this policy is informational and does not guarantee coverage; providers must reference current professional coding guidance and the Health Plan’s benefit language before submitting claims.

    • Codes listed (e.g., J9601) are for reference only; confirm coding and coverage with plan documents prior to claim submission.
    Listed in Appendix A: Abbreviation/Acronym Key
    FLC definition (free light chain)
    TermFLC: free light chain
    Threshold useIn policy, involved FLC ≥ 10 mg/dL (100 mg/L) with abnormal ratio is a measurable disease criterion
    Measurement contextUsed when evaluating measurable disease within last 28 days or when serum/urine M-protein not measurable
    VGPR definition (very good partial response)
    TermVGPR: very good partial response
    Clinical implicationAchievement and maintenance of VGPR or better at/after week 24 enables extended dosing interval (every 4 weeks) per labeling
    ReferenceDefined in Appendix A and referenced in dosing/maintenance guidance
    IMWG progressive disease criteria — increases and thresholds used to define progression
    General ruleIMWG progressive disease is defined by a ≥25% increase from the lowest response value in any specified disease measure
    Serum M component increaseSerum M component: ≥25% increase with an absolute increase of at least 0.5 g/dL
    Urine M component increaseUrine M component: ≥25% increase with an absolute increase of at least 200 mg/24 h
    FLC increase (when serum/urine not measurable)In patients without measurable serum and urine M-protein levels: involved–uninvolved FLC difference increase > 10 mg/dL